<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882609</url>
  </required_header>
  <id_info>
    <org_study_id>AMI-2008-01</org_study_id>
    <nct_id>NCT00882609</nct_id>
  </id_info>
  <brief_title>F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets</brief_title>
  <official_title>18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American College of Radiology - Image Metrix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Molecular Imaging Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>American College of Radiology - Image Metrix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT
      scanning to that of conventional bone scanning for detecting cancer that has spread to the
      bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT
      will lead to improved treatment and patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will accrue four hundred-eighty eight (488) evaluable patients with breast cancer,
      prostate cancer or lung cancer (approximately 163 of each cancer type) referred for routine
      bone scanning by their respective physicians. The specific stages of cancer required for
      eligibility are described in the eligibility criteria.

      Approximately eleven to fifteen qualified clinical centers will participate in the trial,
      with target enrollment for each site set at roughly 40-50 patients per site.

      The images of the patients will be transmitted to ACR Image Metrix, an imaging contract
      research organization (iCRO), for quality assurance and archival. iCRO will conduct blinded
      core lab interpretations by 3 radiologists who have not been involved in the design of the
      trial nor the clinical image interpretation. The data from the core lab readings will be
      compared with the deliberations of a multidisciplinary panel of oncology experts who will be
      blinded to the initial scan results and will determine the standard of evidence (truth) for
      each patient. The analysis will be based on this comparison.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the diagnostic performance of [18F]NaF fluoride PET/CT scanning</measure>
    <time_frame>6 Months</time_frame>
    <description>The primary endpoint will be an analysis of the diagnostic performance of [18F]NaF fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The hypothesis is that PET/CT is superior to conventional bone scanning for detecting bone metastases. The primary metrics used for comparison will be the relative areas under the ROC curves generated by blinded core lab interpretations of the scans.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>TC-MDP Bone Scan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA &gt;10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F18-Fluoride PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA &gt;10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone Scan: F18-Fluoride PET/CT or TC-MDP</intervention_name>
    <description>Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.</description>
    <arm_group_label>TC-MDP Bone Scan</arm_group_label>
    <arm_group_label>F18-Fluoride PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 18 years old at the time of the drug administration (Patient may be male
             or female of any race / ethnicity.)

          -  Patient or patient's legally acceptable representative cognitively provides written
             informed consent

          -  Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast
             cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA &gt;10
             micrograms/L), including patient with recurrent breast, lung or prostate cancer

          -  Patient is scheduled to undergo a conventional bone scan

          -  Patient is capable of complying with study procedures

          -  Patient is able to remain still for duration of imaging procedure (about one hour)

          -  Patient may have had a prior PET or PET/CT scan for staging/restaging.

        Exclusion Criteria:

          -  Patient is &lt; 18 years old at the time of the drug administration

          -  Patient is pregnant or nursing;

               -  testing on site at the institution (urine or serum ßHCG) within 24 hours prior to
                  the start of investigational product administration

               -  obtaining surgical history (e.g., tubal ligation or hysterectomy)

               -  confirming the subject is post menopausal, with a minimum 1 year without menses

          -  Patient has any other condition or personal circumstance that, in the judgment of the
             investigator, might interfere with the collection of complete good quality data

          -  Patient has known bone metastases

          -  Patient has previously received [18F]NaF in the last thirty days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>World Molecular Imaging Society</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Czernin, MD</last_name>
    <phone>(310) 983-1443</phone>
    <email>JCzernin@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scottsdale Medical Imaging</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85252</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jocelyn Harmon</last_name>
      <phone>480-425-4181</phone>
      <email>jharmon@esmil.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Korn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silicon Valley Imaging</name>
      <address>
        <city>Freemont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cedar-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>VA West Los Angles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gholam Berenji, MD</last_name>
      <phone>310-478-3711</phone>
    </contact>
    <investigator>
      <last_name>Gholam Berenji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin A Auerbach, MD</last_name>
      <phone>310-983-1444</phone>
      <email>mauerbach@mednet.ucla.net</email>
    </contact>
    <investigator>
      <last_name>Martin Auerbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindee Burton</last_name>
      <phone>650-725-4712</phone>
      <email>lburton@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Samjiv Gambhir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SouthCoast Imaging Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Couturier</last_name>
      <phone>912-691-4200</phone>
      <email>ncouturier@southcoastmedical.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Wernette</last_name>
      <phone>734-936-5894</phone>
      <email>krisw@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Morand Piert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trent West</last_name>
      <phone>816-932-3502</phone>
    </contact>
    <investigator>
      <last_name>Pablo Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Cochran Veterans Administration</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Warhoover</last_name>
      <phone>314-289-7925</phone>
      <email>ryan.warhoover@va.gov</email>
    </contact>
    <investigator>
      <last_name>Medhat Osman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Edwards</last_name>
      <phone>314-577-8048</phone>
      <email>edwardsm@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Medhat Osman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lenz</last_name>
      <phone>603-653-3520</phone>
      <email>suzanne.b.lenz@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Seltzer Marc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ame Ng</last_name>
      <phone>212-746-2194</phone>
      <email>ameng@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Pablo Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Kidd</last_name>
      <phone>713-563-0633</phone>
    </contact>
    <investigator>
      <last_name>Homer Macapinlac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britney Beardmore</last_name>
      <phone>801-585-0176</phone>
      <email>britney.beardmore@hcu-utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Regan Butterfield</last_name>
      <email>regan.butterfield@hcu-utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Hoffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Drummond</last_name>
      <phone>61 3 9656 1856</phone>
      <email>elizabeth.drummond@petermac.org</email>
    </contact>
    <investigator>
      <last_name>Michael Hofman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PET-CT Linz - St. Vicent's Hospital</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen Beheshti, MD</last_name>
      <phone>43 732 7677 7077</phone>
    </contact>
    <investigator>
      <last_name>Werner Langsteger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Lapa, MD</last_name>
      <phone>351 239 400615</phone>
      <email>paulalapa@huc.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Joao de Lima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone metastasis</keyword>
  <keyword>bone metastases</keyword>
  <keyword>Sodium Fluoride</keyword>
  <keyword>F18 Fluoride</keyword>
  <keyword>bone scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
    <mesh_term>Listerine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

